Volume 14 - Issue 9 - September, 2002
Compression of Venous Insufficiency Ulcers
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 4968 reads
This month the Evidence Corner brings you evidence on compression of venous insufficiency ulcers. Though it is the keystone of conservative management of venous insufficiency ulcers, compression therapy is surrounded by controversy. A Cochrane review examines the evidence on what levels and types of compression work to heal venous ulcers, while a literature summary alerts readers on how to apply that compression and other key variables, which will determine whether the compression your patients are receiving will deliver the outcomes they need.
Compression for Venous Leg Ulcers
Cullu
October
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 1002 reads
Johnson & Johnson Wound Management Introduces High-Performance Alginate Dressing
Johnson & Johnson Wound Management introduces NU-DERM* Alginate Wound Dressing, the high-performance, high-value alginate dressing, to its line of advanced wound care products. In independent laboratory tests, NU-DERM Dressing was shown to be more absorbent than similar dressings and up to six times stronger.
It is estimated that more than four million people suffer from chronic wounds costing as much as $80,000 to treat in some cases. NU-DERM Dressing offers outstanding absorbent capacity, which means fewer
October
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 1533 reads
Healthpoint Receives Patent Application Notice of Allowance for Trademarked Xenaderm™ Ointment Vehicle
Paul Dorman, CEO and Chairman of DFB Pharmaceuticals, Inc., and Healthpoint, Ltd., announces that the United States Patent and Trademark Office has granted Healthpoint a Notice of Allowance on its patent application for the ointment vehicle that is the basis for Healthpoint’s Xenaderm™, a prescription-only ointment that promotes healing and acts as a protective covering for wounds.
Healthpoint, Ltd., a DFB Pharmaceuticals affiliate, applied for the patent when it launched Xenader
Pyoderma Gangrenosum
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 4281 reads
Department Editor: Tania Phillips, MD, FRCPC
Overall Learning Objectives: The physician or podiatrist participant will develop a rational approach to the evaluation and treatment of a variety of uncommon wounds and will have an increased awareness of the differential diagnosis of cutaneous wounds and the systemic diseases associated with these wounds.
Submissions: To submit a case for consideration in Diagnostic Dilemmas, e-mail or write to: Executive Editor, WOUNDS, 83 General Warren Blvd., Suite 100, Malvern, PA 19355, eklumpp@hmpcommunications.com
Completio
Cutaneous Manifestations of Diabetes
- Thu, 9/4/08 - 11:52am
- 1 Comments
- 7805 reads
Introduction
Diabetes mellitus (DM) is a heterogenous group of metabolic disorders characterized by elevated serum glucose levels resulting from defects in insulin production, insulin action, or a combination. Complications include retinopathy, nephropathy, and neuropathy. The two main types of diabetes of are Type 1 insulin-dependent DM, which is characterized by the destruction of insulin-producing beta cells of the pancreas creating the absolute need for exogenous insulin,
Behçet’s Disease: A Clinical Review
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 5236 reads
Introduction
In 1937, Hulusi Behçet, a Turkish dermatologist, described a syndrome characterized by recurrent oral ulcers, genital ulcers, and hypopyon uveitis of unknown cause.1 Over time, Behçet’s disease has come to be recognized as a complex, multisystem, inflammatory disease characterized not only by the above symptoms but also by vascular, neurologic, articular, pulmonary, and gastrointestinal involvement. The diverse range of clinical findings seems to stem from an underlying vasculitis; however, the ultimate etiologic agent remains unknown.
Epidemiology
Although fi
Necrotizing Fasciitis
- Thu, 9/4/08 - 11:52am
- 1 Comments
- 8211 reads
Introduction
Necrotizing fasciitis (NF) is a rare, life-threatening, soft-tissue infection characterized by rapidly spreading inflammation and necrosis of the skin, subcutaneous fat, and fascia.1 The incidence of NF in adults has been reported to be 0.40 cases per 100,000 population, while the incidence in children is 0.08 cases per 100,000 population.2,3 Despite the uncommon nature of this condition, over the last decade, there has been a five-fold increase in the incidence of NF.4 Although largely unexplained, the aging of the population and the increase in numbers of
A Prospective, Randomized, Comparative Study of Collagenase and Papain-Urea for Pressure Ulcer Debridement
- Thu, 9/4/08 - 11:52am
- 0 Comments
- 4852 reads
Introduction
Research studies have demonstrated that devitalized tissue present in pressure ulcers enhances bacterial growth, reduces resistance to infection, delays the formation of granulation tissue, and impedes reepithelialization.1–6 Debridement is necessary for healing and is considered a cornerstone of pressure ulcer care.6–8 Surgical or sharp debridement describes the use of surgical instruments, such as scissors, scalpels, dermatomes, or curettes, to remove devitalized tissue. This is the fastest type of debridement, but it is invasive, may require anesthesia and/
_sm.jpg)
